Abstract

CYP3A4 GENE ROLE IN MULTIDRUG RESISTANCE IN DIABETIC COMPLICATION

Snowbar Akbar, Eliakunda Geofrey Mtaita, Minu Sah, Mohammad Sayam, Shalu Kashyap and Vishal Kajla*

.

Abstract

The CYP3A4 gene, which belongs to the cytochrome P450 enzyme family, is essential for the metabolism of drugs, especially in the liver. The phenomenon known as multidrug resistance (MDR) occurs when cells develop resistance to several chemically unrelated medications. This presents a serious problem in the treatment of several diseases, including problems from diabetes. Hyperglycemia is the hallmark of diabetes, a metabolic disease that frequently requires multiple therapy due to its associated consequences, which include retinopathy, neuropathy, and nephropathy. Patients with diabetes may have higher metabolism and reduced drug efficacy from CYP3A4 overexpression or improved activity, which can exacerbate multidrug resistance (MDR). Furthermore, deregulation of CYP3A4 activity in diabetic patients may also be involved in drug-drug interactions, which could exacerbate multidrug resistance and complicate treatment plans even more. The pharmacokinetics and pharmacodynamics of co-administered medications may change as a result of these interactions, raising the possibility of side effects or producing less than ideal therapeutic results. To optimize treatment approaches, it is essential to comprehend how CYP3A4 gene expression, drug metabolism, and MDR interact with diabetic complications. The development of customized medicine strategies that take into consideration individual genetic variations in CYP3A4 expression holds promise for enhancing treatment results and reducing MDR. In conclusion, the complex interplay among the CYP3A4 gene, multidrug resistance, and diabetic complications highlights the necessity of customized interventions and the significance of continued research in this area to effectively address the clinical challenges related to managing diabetic complications.

Keywords: CYP3A4 gene, multidrug resistance, diabetic complications, drug metabolism, personalized medicine.